The Virtual DCCT: Adding Continuous Glucose Monitoring to a Landmark Clinical Trial for Prediction of Microvascular Complications.

Objective: Using a multistep machine-learning procedure, add virtual continuous glucose monitoring (CGM) traces to the original sparse data of the landmark Diabetes Control and Complications Trial (DCCT). Assess the association of CGM metrics with the microvascular complications of type 1 diabetes observed during the DCCT and establish time-in-range (TIR) as a viable marker of glycemic control. Research Design and Methods: Utilizing the DCCT glycated hemoglobin data obtained every 1 or 3 months plus quarterly 7-point blood glucose (BG) profiles in a multistep procedure: (i) utilized archival BG traces to model interday BG variability and estimate glycated hemoglobin; (ii) trained across the DCCT BG profiles and associated each profile with an archival BG trace; and (iii) used previously identified CGM "motifs" to associate a CGM trace to a BG trace, for each DCCT participant. Results: TIR (70-180 mg/dL) computed from virtual CGM data over 14 days prior to each glycated hemoglobin measurement reproduced the observed glycemic control differences between the intensive and conventional DCCT groups, with TIR generally >60% and <40% in these groups, respectively. Similar to glycated hemoglobin, TIR was associated with the risk of development or progression of retinopathy, nephropathy, and neuropathy (all P-values <0.0001). Poisson regressions indicated that TIR predicted retinopathy and microalbuminuria similarly to the original glycated hemoglobin data. Conclusions: The landmark DCCT was revisited using contemporary data science methods, which allowed adding individual CGM traces to the original data. Fourteen-day CGM metrics predicted microvascular diabetes complications similarly to glycated hemoglobin. Clinical Trials Registration: Not a clinical trial.